Topical Icariin on Acne and Acne Scars
Status
Conditions
Treatments
Details and patient eligibility
About
The goal of this clinical trial is to examine whether topical application of icariin can improve acne and atrophic acne scars in adults. The main questions it aims to answer are:
- Does icariin reduce the number of facial acne lesions and acne scars?
- What histological changes occur in acne or scar tissue after using icariin? Researchers will compare icariin to a vehicle control (3% ethanol solution) to assess its relative efficacy.
Participants will:
- Apply icariin or control solution to each side of the face twice daily for 2 months
- Visit the clinic every 4 weeks for checkup
- Receive skin biopsies before and after the study period, if they consent to this procedure
Full description
Acne vulgaris is one of the most common dermatologic conditions, affecting more than 80-90% of adolescents worldwide. Its pathogenesis is multifactorial, involving excessive sebum production, follicular hyperkeratinization, proliferation of Cutibacterium acnes, and inflammation. Clinical manifestations range from comedones and papules to pustules and nodules, most frequently appearing on the face. Beyond the physical burden, facial acne induces significant psychosocial distress, including anxiety, depression, and social withdrawal. Inflammatory lesions frequently progress to atrophic scars, which persist long term and further intensify psychological morbidity. Studies report acne scarring in up to 95% of patients, with approximately 30% developing scars that are severe enough to require clinical intervention.
Current treatments for atrophic acne scars-such as laser resurfacing, chemical peels, microneedling, and soft-tissue fillers-entail risks including pain, prolonged downtime, and variable efficacy. Topical pharmacologic agents, including retinoids, offer noninvasive alternatives, but their scar-remodeling effects are limited and may cause irritation or photosensitivity. Because scar formation involves a complex interplay of inflammation, collagen degradation, and impaired wound healing, there remains an unmet need for therapies that are safe, effective, and accessible, capable of addressing both active acne and established scars.
Icariin is a prenylated flavonoid glycoside isolated from Epimedium species (e.g., Yin Yang Huo, horny goat weed), traditionally used in oriental medicine as an herbal remedy and dietary tincture. It has demonstrated neuroprotective, cardiovascular, anti-osteoporotic, and antitumor effects, and is considered safe for human consumption. Preclinical evidence indicates that icariin inhibits inflammation, regulates lipid metabolism, suppresses bacterial proliferation, and promotes skin wound healing. Despite these properties, which suggest both anti-acne and pro-remodeling potential, no clinical study to date has evaluated icariin's efficacy in human acne or acne scars.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Adults aged 19 to 39 with inflammatory acne and atrophic acne scars on both sides of the face
Exclusion criteria
- Diagnosis of acne conglobata or acne fulminans
- Pregnancy or breastfeeding
- Presence of systemic diseases or use of medications that may affect acne or scarring
- Presence of psychiatric disorders
- Recent use of isotretinoin within the past 4 months
- Use of other oral or topical acne treatments or anti-acne cosmetics within the past 2 weeks
- Receipt of procedural treatment for acne scars (e.g. chemical peels or energy-based devices) within the past 4 weeks
Trial design
Primary purpose
Allocation
Interventional model
Masking
25 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal